Loading
Vaccine Development / Vaccines / Adjuvants, Vaccine · Journal article
Expert Review of Vaccines · August 21, 2026
A consensus or society position rather than new primary data.
This is a comprehensive expert review that presents trained immunity as a mechanistic framework for rational vaccine adjuvant design, moving beyond empiricism toward engineered strategies targeting innate immune reprogramming. The review synthesizes emerging approaches including natural inducers, synthetic pattern-recognition receptor agonists, metabolic modulators, and self-adjuvanting antigens, but does not report efficacy outcomes from clinical or pivotal preclinical trials.
Journal article.
Trained immunity offers a mechanistic basis for enhanced protection against heterologous pathogens in specific conditions Core mechanism involves PI3K/Akt/mTOR/HIF1α-driven immunometabolic switch and chromatin rewiring Emerging adjuvant strategies span natural TI inducers, synthetic pattern-recognition receptor agonists, direct metabolic-epigenetic modulators, and self-adjuvanting antigens
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review frames trained immunity as a mechanistic direction for next-generation adjuvant development and offers a conceptual roadmap; however, it does not provide direct clinical evidence to guide immediate changes in vaccine practice. Professionals should regard it as a synthesis of emerging science identifying opportunities and barriers to clinical translation.
A comprehensive expert review synthesizing mechanistic foundations and emerging strategies for trained immunity-based vaccine adjuvants, providing a conceptual framework and translational roadmap rather than reporting original experimental or clinical data.
This review frames trained immunity as a mechanistic direction for next-generation adjuvant development and offers a conceptual roadmap; however, it does not provide direct clinical evidence to guide immediate changes in vaccine practice. Professionals should regard it as a synthesis of emerging science identifying opportunities and barriers to clinical translation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Introduction. The paradigm of trained immunity (TI), a de facto innate immune memory mediated by metabolic and epigenetic reprogramming of innate leukocytes, has expanded the conceptual framework for rational vaccine adjuvant design. Moving beyond conventional empiricism, TI offers a mechanistic basis that may enhance protection against certain heterologous pathogens, particularly in specific conditions.Areas covered. This review provides a comprehensive analysis of next-generation adjuvants engineered to induce TI. We outline the core mechanistic foundations encompassing the PI3K/Akt/mTOR/HIF1α-driven immunometabolic switch and ensuing chromatin rewiring, categorize emerging adjuvant strategies from natural TI inducers to synthetic pattern-recognition receptor agonists, direct metabolic-epigenetic modulators, and self-adjuvanting antigens, examine the enabling role of nanotechnology in achieving spatiotemporal control, and discuss translational roadmaps, safety considerations, and pivotal challenges.Expert opinion. TI-inducing adjuvants provide a mechanistic basis for bridging innate and adaptive immunity and represent a promising direction for next-generation vaccine development. Realizing their full potential will require resolving critical challenges in precision-tunability, host heterogeneity, and durability of the trained state, alongside defining validated correlates of protection. The convergence of systems immunology and advanced delivery platforms might accelerate the transition from concept to clinical vaccines, and contribute to the improved preparedness against infectious and noninfectious diseases.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.